Molecular Partners Ag Stock Fundamentals
| MOLN Stock | USD 5.29 0.13 2.40% |
Molecular Partners AG fundamentals help investors to digest information that contributes to Molecular Partners' financial success or failures. It also enables traders to predict the movement of Molecular Stock. The fundamental analysis module provides a way to measure Molecular Partners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Partners stock.
At this time, Molecular Partners' Income Tax Expense is very stable compared to the past year. As of the 25th of November 2024, Net Interest Income is likely to grow to about 3.9 M, while Depreciation And Amortization is likely to drop about 2 M. Molecular | Select Account or Indicator |
Molecular Partners AG Company Return On Asset Analysis
Molecular Partners' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Molecular Partners Return On Asset | -0.21 |
Most of Molecular Partners' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Molecular Total Assets
Total Assets |
|
Based on the latest financial disclosure, Molecular Partners AG has a Return On Asset of -0.2117. This is 97.58% lower than that of the Biotechnology sector and 99.1% lower than that of the Health Care industry. The return on asset for all United States stocks is 51.21% higher than that of the company.
Molecular Partners Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Molecular Partners's current stock value. Our valuation model uses many indicators to compare Molecular Partners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecular Partners competition to find correlations between indicators driving Molecular Partners's intrinsic value. More Info.Molecular Partners AG is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Molecular Partners' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Molecular Partners' earnings, one of the primary drivers of an investment's value.Molecular Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in return on asset category among its peers.
Molecular Partners Current Valuation Drivers
We derive many important indicators used in calculating different scores of Molecular Partners from analyzing Molecular Partners' financial statements. These drivers represent accounts that assess Molecular Partners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Molecular Partners' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 548.7M | 387.4M | 552.5M | 200.0M | 112.7M | 107.1M | |
| Enterprise Value | 417.3M | 288.4M | 486.7M | 116.9M | 49.1M | 46.6M |
Molecular Partners ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Molecular Partners' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Molecular Partners' managers, analysts, and investors.Environmental | Governance | Social |
Molecular Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (21.42) % | ||||
| Current Valuation | 42.6 M | ||||
| Shares Outstanding | 36.84 M | ||||
| Shares Owned By Institutions | 5.31 % | ||||
| Number Of Shares Shorted | 57.05 K | ||||
| Price To Earning | 1.85 X | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 33.56 X | ||||
| Revenue | 7.04 M | ||||
| Gross Profit | 138.85 M | ||||
| EBITDA | (59.53 M) | ||||
| Net Income | (61.98 M) | ||||
| Cash And Equivalents | 267.13 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 3.65 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.37 X | ||||
| Book Value Per Share | 4.18 X | ||||
| Cash Flow From Operations | (59.01 M) | ||||
| Short Ratio | 1.69 X | ||||
| Earnings Per Share | (2.13) X | ||||
| Target Price | 9.33 | ||||
| Number Of Employees | 167 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 201.42 M | ||||
| Total Asset | 198.35 M | ||||
| Retained Earnings | (191.75 M) | ||||
| Working Capital | 178.04 M | ||||
| Net Asset | 198.35 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.3 M | 4.1 M | |
| Total Revenue | 7 M | 6.7 M | |
| Cost Of Revenue | 47.8 M | 30.4 M | |
| Stock Based Compensation To Revenue | 0.74 | 0.78 | |
| Sales General And Administrative To Revenue | 2.70 | 2.83 | |
| Research And Ddevelopement To Revenue | 6.93 | 7.28 | |
| Capex To Revenue | 0.08 | 0.06 | |
| Revenue Per Share | 0.21 | 0.20 | |
| Ebit Per Revenue | (8.68) | (8.25) |
Pair Trading with Molecular Partners
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Molecular Partners position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will appreciate offsetting losses from the drop in the long position's value.Moving against Molecular Stock
The ability to find closely correlated positions to Molecular Partners could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Molecular Partners when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Molecular Partners - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Molecular Partners AG to buy it.
The correlation of Molecular Partners is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Molecular Partners moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Molecular Partners moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Molecular Partners can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Molecular Partners Piotroski F Score and Molecular Partners Altman Z Score analysis. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.13) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.73) | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.